Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Tacrolimus Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy N/A

    Initial Prior Authorization Tacrolimus Ointment

    Customize your policy alerts

    Sign up for all cvs_caremark policy alerts

    Know when cvs_caremark releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization for tacrolimus ointment, including 0.03% and 0.1% strengths, for atopic dermatitis, psoriasis, and vitiligo. It applies to requests for both generic tacrolimus ointment and all dosage forms and strengths referenced by the document.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Tacrolimus Ointment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the diagnosis, treatment site, requested strength, and applicable prior therapy or clinical response for authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered indications
    0.03% and 0.1%Strengths addressed
    3 monthsInitial approval
    12 or 36 monthsContinuation approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age and strength
    Restrictions

    Covered Indications and Restrictions

    Atopic dermatitis initial therapy

    Authorization may be granted when all of the following are met:

    Atopic dermatitis initial authorization

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway

        • Qualifying criterion

          • Age criterion: The patient is less than 2 years of age.<2 years
          • Sensitive-site criterion: The requested drug will be used on sensitive skin areas such as the face, genitals, or skin folds.
          • First-line therapy criterion: The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroid.At least 1 first-line agent
      • Tacrolimus 0.1% pathway

        • Qualifying criterion

          • Sensitive-site criterion: The requested drug will be used on sensitive skin areas such as the face, genitals, or skin folds.
          • First-line therapy criterion: The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroid.At least 1 first-line agent

    Psoriasis initial therapy

    Authorization may be granted when all of the following are met:

    Psoriasis initial authorization

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Vitiligo initial therapy

    Authorization may be granted when all of the following are met:

    Vitiligo initial authorization

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Atopic dermatitis continuation therapy

    Authorization may be granted when all of the following are met:

    Atopic dermatitis continuation

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Psoriasis continuation therapy

    Authorization may be granted when all of the following are met:

    Psoriasis continuation

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Vitiligo continuation therapy

    Authorization may be granted when all of the following are met:

    Vitiligo continuation

    • Strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Tacrolimus ointment is not indicated for children younger than 2 years of age.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Criteria

    Initial authorization may be granted for tacrolimus ointment when the requested indication, strength, age, treatment site, and applicable first-line therapy requirements are met.

    • Atopic dermatitis: Short-term and noncontinuous chronic treatment of moderate to severe eczema. Requirements vary by strength and are detailed in the related documentation and first-line therapy criteria below.
    • Psoriasis: Treatment must be for lesions on the face, genitals, or skin folds. Tacrolimus 0.03% is eligible; tacrolimus 0.1% requires the patient to be 16 years of age or older.
    • Vitiligo: Treatment must be for lesions on the head or neck. Tacrolimus 0.03% is eligible; tacrolimus 0.1% requires the patient to be 16 years of age or older.
    Prior Authorization

    Continuation Authorization Criteria

    Continuation authorization may be granted when the patient has achieved or maintained a positive clinical response and the requested strength and age requirements are met.

    Initial Authorization Pathways

    Atopic dermatitis initial therapy

    Authorization may be granted when all of the following are met:

    Atopic dermatitis indication

    • Applicable strength-specific pathway

      • Tacrolimus 0.03% pathway

        • Qualifying criterion

          • The patient is less than 2 years of age.<2 years
          • The requested drug will be used on sensitive skin areas such as the face, genitals, or skin folds.

    Continuation Authorization Pathways

    Atopic dermatitis continuation

    Authorization may be granted when all of the following are met:

    • Applicable strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Psoriasis continuation

    Authorization may be granted when all of the following are met:

    Required First-Line Treatment

    StepFirst-line therapy requirementRequired outcome
    1At least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroidInadequate treatment response, intolerance, or contraindication

    Clinical Context

    Tacrolimus ointment is addressed as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have not responded adequately to other topical prescription treatments or for whom those treatments are not advisable.

    Policy Definitions

    Short-term and non-continuous chronic treatment
    Treatment patternShort-term and non-continuous chronic treatment
    ConditionModerate to severe atopic dermatitis (eczema)
    Therapeutic roleSecond-line therapy for patients who have not responded adequately to other topical prescription treatments or for whom those treatments are not advisable
    Positive clinical response in atopic dermatitis
    Positive responseImprovement in or resolution of one or more signs or symptoms of atopic dermatitis
    Erythema and edemaReduced redness and swelling
    Xerosis
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Tacrolimus Ointment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the diagnosis, treatment site, requested strength, and applicable prior therapy or clinical response for authorization.
    SourceLink
    On This Page
    Covered Indications and RestrictionsAuthorization and Documentation RequirementsInitial Authorization PathwaysContinuation Authorization PathwaysRequired First-Line TreatmentClinical ContextPolicy Definitions
  1. Atopic dermatitis: The drug must continue to be used for short-term and noncontinuous chronic treatment of moderate to severe eczema. Tacrolimus 0.03% is eligible; tacrolimus 0.1% requires the patient to be 16 years of age or older.
  2. Psoriasis: Treatment must remain for the face, genitals, or skin folds. Tacrolimus 0.03% is eligible; tacrolimus 0.1% requires the patient to be 16 years of age or older.
  3. Vitiligo: Treatment must remain for the head or neck. Tacrolimus 0.03% is eligible; tacrolimus 0.1% requires the patient to be 16 years of age or older.
  4. Step Therapy

    First-Line Therapy Requirement

    For atopic dermatitis, document failure of or inability to use qualifying first-line treatment when required by the requested strength and clinical circumstances.

    • Document an inadequate treatment response, intolerance, or contraindication to at least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroid.
    • For tacrolimus 0.03%, this requirement is one qualifying pathway, along with use on sensitive skin areas.
    • For tacrolimus 0.1%, the patient must be at least 16 years old and must either have qualifying first-line therapy history or require treatment on sensitive skin areas.
    Documentation Required

    Atopic Dermatitis Clinical Documentation

    Submit clinical documentation supporting moderate to severe atopic dermatitis (eczema), the requested tacrolimus strength, the patient's age, and the treatment history or site supporting the request.

    • Document that treatment is for short-term and noncontinuous chronic management in a non-immunocompromised patient.
    • For requests involving sensitive skin, identify the site, such as the face, genitals, or skin folds.
    • Include the relevant inadequate response, intolerance, or contraindication to at least one qualifying first-line agent when applicable.
    Documentation Required

    Diagnosis and Treatment Site

    Document the covered diagnosis and qualifying anatomical treatment site for psoriasis or vitiligo requests.

    • Psoriasis: The requested drug must be used on the face, genitals, or skin folds.
    • Vitiligo: The requested drug must be used on the head or neck.
    • For either indication, document the requested tacrolimus strength and patient age when requesting 0.1% ointment.
    Documentation Required

    Continuation Response Documentation

    Continuation requests require documentation that the patient has achieved or maintained a positive clinical response to tacrolimus.

    • Atopic dermatitis: Document improvement in or resolution of signs or symptoms such as erythema, edema, xerosis, erosions, excoriations, oozing and crusting, lichenification, or pruritus.
    • Psoriasis: Document improvement, such as a clear or almost clear outcome or patient satisfaction.
    • Vitiligo: Document meaningful repigmentation or other clinically relevant improvement.
    Denial Risk

    Atopic Dermatitis Criteria Not Met

    An atopic dermatitis request is not approvable when the indication, age, strength, treatment site, or required first-line therapy criteria are not satisfied.

    • Tacrolimus ointment is not indicated for children younger than 2 years of age.
    • Tacrolimus 0.1% ointment requires the patient to be 16 years of age or older.
    • The request must be for moderate to severe atopic dermatitis and short-term or noncontinuous chronic treatment.
    • When relying on treatment history, there must be documented inadequate response, intolerance, or contraindication to at least one qualifying first-line therapy agent.
    • When relying on site-specific criteria, the requested drug must be used on sensitive skin areas such as the face, genitals, or skin folds.
    Denial Risk

    Unapproved Treatment Site

    Psoriasis and vitiligo requests may be denied when the documented diagnosis or treatment location is outside the covered anatomical sites.

    • Psoriasis: Qualifying sites are limited to the face, genitals, or skin folds.
    • Vitiligo: Qualifying sites are limited to the head or neck.
    • Treatment at other sites does not meet the stated authorization criteria.
    Denial Risk

    No Documented Clinical Response

    Continuation authorization may be denied when the record does not document that the patient achieved or maintained a positive clinical response.

    • Atopic dermatitis requires documented improvement in or resolution of relevant signs or symptoms.
    • Psoriasis requires documented improvement, such as a clear or almost clear outcome or patient satisfaction.
    • Vitiligo requires documented improvement, such as meaningful repigmentation.
    Denial Risk

    Age Restriction for 0.1% Strength

    The 0.1% strength has an age restriction across the covered indications: the patient must be 16 years of age or older for initial or continuation authorization.

    • For atopic dermatitis, tacrolimus 0.1% is restricted to patients age 16 years or older.
    • For psoriasis and vitiligo, tacrolimus 0.1% is restricted to patients age 16 years or older.
    • Tacrolimus 0.03% is the strength available under the stated criteria for younger patients; tacrolimus ointment is not indicated for children younger than 2 years of age.
    The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroid.At least 1 first-line agent
  5. Tacrolimus 0.1% pathway

    • Qualifying criterion

      • The requested drug will be used on sensitive skin areas such as the face, genitals, or skin folds.
      • The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first-line therapy agent, such as a medium- or higher-potency topical corticosteroid.At least 1 first-line agent
  6. Psoriasis initial therapy

    Authorization may be granted when all of the following are met:

    Psoriasis indication and treatment site

    • Applicable strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years

    Vitiligo initial therapy

    Authorization may be granted when all of the following are met:

    Vitiligo indication and treatment site

    • Applicable strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years
  7. Applicable strength-specific pathway

    • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
    • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years
  8. Vitiligo continuation

    Authorization may be granted when all of the following are met:

    • Applicable strength-specific pathway

      • Tacrolimus 0.03% pathway: The request is for tacrolimus 0.03% ointment.
      • Tacrolimus 0.1% pathway: The request is for tacrolimus 0.1% ointment and the patient is 16 years of age or older.>=16 years
    Improvement or resolution of dry skin
    Erosions and excoriationsImprovement or resolution of skin erosions or evidence of scratching
    Oozing and crustingImprovement or resolution of oozing and crusting
    Lichenification and pruritusImprovement or resolution of epidermal thickening or itching